Search Results - "Immunoconjugates therapeutic use"
-
1
Authors: et al.
Contributors: et al.
Source: Nat Med
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instnameSubject Terms: Immunoconjugates, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Oncologie, Medicaments antineoplàstics - Ús terapèutic, Research & Experimental Medicine, DESTINY-Breast12 study group, Antineoplastic Agents, Immunological, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica, Immunoconjugates/adverse effects, Prospective Studies, Human health sciences, 11 Medical and Health Sciences, EXPLORATORY ANALYSIS, CLINICAL-PRACTICE GUIDELINE, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Brain Neoplasms, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal, Middle Aged, Progression-Free Survival, trastuzumab deruxtecan, EMTANSINE T-DM1, Oncology, Medicine, Research & Experimental, ErbB-2/metabolism, Female, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia libre de progresión, Life Sciences & Biomedicine, Receptor, RADIOTHERAPY, RADIOSURGERY, Adult, Biochemistry & Molecular Biology, Receptor, erbB-2, Immunology, SOCIETY, Antineoplastic Agents, Brain Neoplasms/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Progression-Free Survival, Breast Neoplasms, CAPECITABINE, Sciences de la santé humaine, Article, Immunological/therapeutic use, Breast Neoplasms/drug therapy, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological, Humans, Immunoconjugates/therapeutic use, Aged, Trastuzumab/therapeutic use, Science & Technology, 42 Health sciences, ERBB2 protein, human, Cell Biology, 32 Biomedical and clinical sciences, Trastuzumab, EFFICACY, DS-8201A, Mama - Càncer - Tractament, Avaluació de resultats (Assistència sanitària), Brain Neoplasms/secondary, Camptothecin/analogs & derivatives, Camptothecin, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/39271844
https://hdl.handle.net/11351/12359
https://cris.maastrichtuniversity.nl/en/publications/5907550f-729b-40c9-900e-d22721072849
https://doi.org/10.1038/s41591-024-03261-7
https://www.nature.com/articles/s41591-024-03261-7#article-info
https://doi.org/10.1038/s41591-024-03261-7
https://hdl.handle.net/20.500.11768/172577
https://www.nature.com/articles/s41591-024-03261-7
https://doi.org/10.1038/s41591-024-03261-7
https://lirias.kuleuven.be/handle/20.500.12942/750006
https://doi.org/10.1038/s41591-024-03261-7
https://hdl.handle.net/2268/328027
https://doi.org/10.1038/s41591-024-03261-7
https://portal.findresearcher.sdu.dk/da/publications/06812573-f19e-46ad-8295-e6fc0b9f1d28
https://doi.org/10.1038/s41591-024-03261-7 -
2
Authors: et al.
Contributors: et al.
Source: EMBO Mol Med
EMBO Molecular Medicine, Vol 16, Iss 9, Pp 2233-2261 (2024)
Chen, H C, Mueller, N, Stott, K, Kapeni, C, Rivers, E, Sauer, C M, Beke, F, Walsh, S J, Ashman, N, O’Brien, L, Rafati Fard, A, Godsinia, A, Li, C, Joud, F, Giger, O, Zlobec, I, Olan, I, Aitken, S J, Hoare, M, Mair, R, Serrao, E, Brenton, J D, Garcia-Gimenez, A, Richardson, S E, Huntly, B, Spring, D R, Skjoedt, M O, Skjødt, K, de la Roche, M & de la Roche, M 2024, ' Novel immunotherapeutics against LGR5 to target multiple cancer types ', EMBO Molecular Medicine, vol. 16, no. 9, pp. 2233-2261 . https://doi.org/10.1038/s44321-024-00121-2Subject Terms: Medicine (General), Immunoconjugates, QH426-470, Article, Cell Line, Receptors, G-Protein-Coupled, BiTE, Mice, R5-920, LGR5, Cell Line, Tumor, Neoplasms, Receptors, Genetics, Neoplasms/therapy, Humans, Animals, Immunoconjugates/therapeutic use, G-Protein-Coupled/metabolism, Tumor, Animal, Cancer Immunotherapeutics, CAR, 3. Good health, Disease Models, Animal, ADC, Disease Models, Immunotherapy/methods, Immunotherapy
File Description: application/pdf; application/zip; text/xml
-
3
Authors: et al.
Source: Nature
Subject Terms: Male, 0301 basic medicine, Immunoconjugates, Hematologic Neoplasms / drug therapy, Article, Mice, 03 medical and health sciences, Antibody Specificity, Cell Line, Tumor, Immunoconjugates / pharmacology, Leukocyte Common Antigens / metabolism, Animals, Humans, Hematopoiesis / drug effects, Hematopoietic Stem Cells / metabolism, Hematopoietic Stem Cells / cytology, 0303 health sciences, Hematologic Neoplasms / therapy, Hematopoietic Stem Cells / drug effects, Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cells, Immunoconjugates / therapeutic use, Hematopoiesis, 3. Good health, Hematologic Neoplasms, Leukocyte Common Antigens, Female, Hematologic Neoplasms / immunology, Leukocyte Common Antigens / immunology
File Description: application/pdf
-
4
Authors: et al.
Contributors: et al.
Source: Future Oncol
Future oncology (London, England), Vol. 20, no.18, p. 1237-1250 (2024)
Future oncology, vol. 20, no. 18, pp. 1237-1250Subject Terms: Receptor, erbB-2, Clinical Trial Protocol, Immunoconjugates, Receptor, ErbB-2, overall survival, Breast Neoplasms, DIAGNOSIS, 3211 Oncology and carcinogenesis, Antineoplastic Combined Chemotherapy Protocols, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Prospective Studies, Neoplasm Staging, Science & Technology, ASSOCIATION, INSTRUMENTS, Trastuzumab, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Female, Receptor, ErbB-2/metabolism, Receptor, ErbB-2/antagonists & inhibitors, Trastuzumab/therapeutic use, Europe, Immunoconjugates/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Treatment Outcome, Research Design, Camptothecin/analogs & derivatives, HER2-low, adverse events, metastatic breast cancer, patient-reported outcomes, progression-free survival, trastuzumab deruxtecan, 3. Good health, [SDV] Life Sciences [q-bio], Oncology, BIAS, GUIDELINE, MENDELIAN RANDOMIZATION, Camptothecin, Life Sciences & Biomedicine
File Description: application/pdf
-
5
Authors: et al.
Source: Virchows Arch
Subject Terms: Immunoconjugates, Female [MeSH], HER2-low, Receptor, ErbB-2/metabolism [MeSH], Humans [MeSH], Breast cancer, Breast Neoplasms/drug therapy [MeSH], Trastuzumab/therapeutic use [MeSH], Breast Neoplasms/metabolism [MeSH], Animals [MeSH], Camptothecin/analogs, Receptor, ErbB-2/analysis [MeSH], Camptothecin/therapeutic use [MeSH], Immunoconjugates/therapeutic use [MeSH], Original Article, Companion diagnostic, Reproducibility of Results [MeSH], Biomarkers, Tumor/metabolism [MeSH], Antineoplastic Agents, Immunological/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Biomarkers, Tumor/analysis [MeSH], 4B5, Immunohistochemistry/methods [MeSH], Breast Neoplasms/pathology [MeSH], Receptor, ErbB-2, Reproducibility of Results, Breast Neoplasms, Trastuzumab, Antibodies, Monoclonal, Humanized, Immunohistochemistry, 3. Good health, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Humans, Animals, Female, Camptothecin
-
6
Authors: et al.
Contributors: et al.
Source: ISSN: 2162-4011.
Subject Terms: Cancer CD47 cell stress immunotherapy, Cancer, CD47, cell stress, immunotherapy, MESH: Animals, MESH: Bystander Effect* / drug effects, MESH: Neoplasms* / immunology, MESH: Neoplasms* / pathology, MESH: Bystander Effect* / immunology, MESH: Humans, MESH: Immunoconjugates* / pharmacology, MESH: Immunoconjugates* / therapeutic use, MESH: Immunogenic Cell Death* / drug effects, MESH: Immunogenic Cell Death* / immunology, MESH: Immunotherapy / methods, MESH: Neoplasms* / drug therapy, [SDV]Life Sciences [q-bio]
Relation: info:eu-repo/semantics/altIdentifier/pmid/40662767; info:eu-repo/grantAgreement//101052444/EU/Immunogenic cell death (ICD) in the cancer-immune dialogue/ICD-Cancer; PUBMED: 40662767; PUBMEDCENTRAL: PMC12269677
-
7
Authors: et al.
Source: Zanchetta, C, De Marchi, L, Macerelli, M, Pelizzari, G, Costa, J, Aprile, G & Cortiula, F 2025, 'Antibody-Drug Conjugates in Non-Small Cell Lung Cancer : State of the Art and Future Perspectives', International Journal of Molecular Sciences, vol. 26, no. 1, 221. https://doi.org/10.3390/ijms26010221
Subject Terms: ADC, NSCLC, Trastuzumab deruxtecan, target therapy, Humans, Immunoconjugates/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy metabolism, Lung Neoplasms/drug therapy metabolism, Animals
Relation: info:eu-repo/semantics/altIdentifier/pissn/1661-6596; info:eu-repo/semantics/altIdentifier/eissn/1422-0067
-
8
Authors: et al.
Source: Microb Biotechnol
Microbial Biotechnology, Vol 16, Iss 7, Pp 1456-1474 (2023)Subject Terms: Staphylococcus aureus, Immunoconjugates, Drug Resistance, Mini Reviews, Staphylococcal Infections/drug therapy, Drug Development, Drug Resistance, Multiple, Bacterial, Humans, Adjuvants, Phage Therapy, Immunoconjugates/therapeutic use, Adjuvants, Pharmaceutic, Biological Products, Bacterial, Drug Synergism, Staphylococcal Infections, 3. Good health, Anti-Bacterial Agents, Anti-Bacterial Agents/therapeutic use, Drug Development/trends, Pharmaceutic/therapeutic use, Biological Products/therapeutic use, Multiple, TP248.13-248.65, Biotechnology, Antimicrobial Cationic Peptides
-
9
'Clone-specific' antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers
Authors:
Source: Signal Transduct Target Ther
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-2 (2024)Subject Terms: Immunoconjugates, QH301-705.5, T-Lymphocytes, Medicine, Humans, research-highlight, Research Highlight, T-Lymphocytes/drug effects [MeSH], T-Lymphocytes/immunology [MeSH], 631/154/152, Humans [MeSH], 692/4028/67/1990, 692/308/153, Immunoconjugates/pharmacology [MeSH], Immunoconjugates/therapeutic use [MeSH], Biology (General)
-
10
Authors: et al.
Source: Nat Commun
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Vidal-Calvo, E E, Martin-Salazar, A, Choudhary, S, Dagil, R, Raghavan, S S R, Duvnjak, L, Nordmaj, M A, Clausen, T M, Skafte, A, Oberkofler, J, Wang, K, Agerbæk, M Ø, Løppke, C, Jørgensen, A M, Ropac, D, Mujollari, J, Willis, S, Garcias López, A, Miller, R L, Karlsson, R T G, Goerdeler, F, Chen, Y-H, Colaço, A R, Wang, Y, Lavstsen, T, Martowicz, A, Nelepcu, I, Marzban, M, Oo, H Z, Ørum-Madsen, M S, Wang, Y, Nielsen, M A, Clausen, H, Wierer, M, Wolf, D, Gögenur, I, Theander, T G, Al-Nakouzi, N, Gustavsson, T, Daugaard, M & Salanti, A 2024, ' Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate ', Nature Communications, vol. 15, no. 1, 7553 . https://doi.org/10.1038/s41467-024-51781-0Subject Terms: 0301 basic medicine, Immunoconjugates, Science, Epitopes/immunology, Article, Cell Line, Mice, Epitopes, 03 medical and health sciences, Antigens, Neoplasm, Peptide Library, Neoplasms, Cell Line, Tumor, Neoplasms/immunology, Animals, Humans, Antigens, Immunoconjugates/therapeutic use, Antigens, Neoplasm/immunology, 0303 health sciences, Tumor, Chondroitin Sulfates, Neoplasm/immunology, Xenograft Model Antitumor Assays, 3. Good health, Chondroitin Sulfates/metabolism, Female
File Description: application/pdf
-
11
Authors: et al.
Source: Nature Medicine, 30 (12), 3717 - 3727 (2024-12)
Subject Terms: Antineoplastic Agents, Immunological, ERBB2 protein, human, Immunoconjugates, Receptor, ErbB-2, trastuzumab deruxtecan, Immunoconjugates/therapeutic use, Immunoconjugates/adverse effects, Progression-Free Survival, Prospective Studies, Brain Neoplasms/secondary, Brain Neoplasms/drug therapy, Breast Neoplasms/drug therapy, Camptothecin/analogs & derivatives, Trastuzumab/therapeutic use, Brain Neoplasms, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie
Relation: https://www.nature.com/articles/s41591-024-03261-7.pdf; urn:issn:1078-8956; urn:issn:1546-170X
Access URL: https://orbi.uliege.be/handle/2268/328027
-
12
Authors: et al.
Contributors: et al.
Source: Clinical Cancer Research. 29:221-232
Subject Terms: Lung Neoplasms, Immunoconjugates, Non-Small-Cell Lung* / genetics, Drug Resistance, Lung Neoplasms* / genetics, Cell Line, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Non-Small-Cell Lung* / pathology, Humans, Protein Kinase Inhibitors / therapeutic use, Protein Kinase Inhibitors, Lung Neoplasms* / pathology, Tumor, Carcinoma, Immunoconjugates* / therapeutic use, Protein Kinase Inhibitors / pharmacology, Neoplasm / genetics, Proto-Oncogene Proteins c-met, Lung Neoplasms* / drug therapy, 3. Good health, ErbB Receptors, Drug Resistance, Neoplasm, Mutation, Non-Small-Cell Lung* / drug therapy
Access URL: https://pubmed.ncbi.nlm.nih.gov/36269795
-
13
Authors: et al.
Contributors: et al.
Source: Cancer Discov
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Cancer Discovery, vol 12, iss 12Subject Terms: CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Breast Neoplasms/pathology, Immunoconjugates, Other subheadings::Other subheadings::/therapeutic use, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Oncologie, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, ErbB-2, 0302 clinical medicine, Human health sciences, ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica, Cancer, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Brain Neoplasms, 3. Good health, trastuzumab deruxtecan, Oncology, Female, Receptor, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Otros calificadores::Otros calificadores::/uso terapéutico, Brain Neoplasms/drug therapy, Breast Neoplasms, Sciences de la santé humaine, 03 medical and health sciences, Metàstasi, Clinical Research, Breast Cancer, Humans, Camptothecin/therapeutic use, Immunoconjugates/therapeutic use, erbB-2, Trastuzumab/therapeutic use, Research Briefs, Biomedical and Clinical Sciences, Prevention, Neurosciences, Oncology and carcinogenesis, Trastuzumab, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis, Biochemistry and cell biology, Mama - Càncer - Tractament, Brain Neoplasms/secondary, Camptothecin, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
File Description: application/pdf
-
14
Authors: et al.
Contributors: et al.
Source: Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Dipòsit Digital de la UB
instname
Modi, S, Jacot, W, Yamashita, T, Sohn, J, Vidal, M, Tokunaga, E, Tsurutani, J, T. Ueno, N, Prat, A, Chae, Y S, Seok Lee, K, Niikura, N, Hee Park, Y, Xu, B, Wang, X, Gil-Gil, M, Li, W, Pierga, J-Y, Im, S-A, C.F. Moore, H, S. Rugo, H, Yerushalmi, R, Zagouri, F, Gombos, A, Kim, S-B, Liu, Q, Luo, T, Saura, C, Schmid, P, Sun, T, Gambhire, D, Young, L, Wang, Y, Singh, J, Vitazka, P, Meinhardt, G, Harbeck, N & Cameron, D A 2022, ' Trastuzumab deruxtecan in previously treated HER2low advanced breast cancer ', New England Journal of Medicine . https://doi.org/DOI: 10.1056/NEJMoa2203690Subject Terms: Immunoconjugates, Breast Neoplasms* / secondary, Receptor, ErbB-2, Humanized / adverse effects, ErbB-2* / genetics, Antineoplastic Agents, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Càncer de mama, Immunological* / therapeutic use, 03 medical and health sciences, Breast cancer, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immunological* / adverse effects, Monoclonal, Humanized / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms* / genetics, Camptothecin / analogs & derivatives, Humans, ErbB-2* / analysis, Breast Neoplasms* / metabolism, Trastuzumab* / adverse effects, 2. Zero hunger, Trastuzumab* / therapeutic use, Immunoconjugates / adverse effects, Sciences bio-médicales et agricoles, Trastuzumab, 16. Peace & justice, Immunohistochemistry, Immunoconjugates / therapeutic use, ErbB-2* / biosynthesis, 3. Good health, Disease Progression, Monoclonal antibodies, Camptothecin, Female, Anticossos monoclonals, Breast Neoplasms* / drug therapy, Receptor
File Description: application/pdf; No full-text files
Access URL: https://pubmed.ncbi.nlm.nih.gov/35665782
https://hdl.handle.net/2445/197309
https://hdl.handle.net/11588/963508
https://www.pure.ed.ac.uk/ws/files/279758838/nejmoa2203690.pdf
https://hdl.handle.net/20.500.11820/4095995e-3067-46c9-875a-a70cdb641427
https://hdl.handle.net/11588/963508
https://doi.org/10.1056/NEJMoa2203690
http://hdl.handle.net/2445/197309 -
15
Authors: et al.
Contributors: et al.
Source: RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
instnameSubject Terms: Immunoconjugates, Lung Neoplasms, Maintenance, Derrame pericárdico, DLL3, Phase 3, Antibodies, Monoclonal, Humanized, Rovalpituzumab tesirine, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Monoclonal, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Inmunoconjugados, Antineoplastic Combined Chemotherapy Protocols, Humans, Humanized, Benzodiazepinones / therapeutic use, Platinum / therapeutic use, Platinum-based chemotherapy, Platinum, Benzodiazepinones, Small cell lung cancer, Immunoconjugates* / therapeutic use, Middle Aged, Lung Neoplasms* / drug therapy, 3. Good health, Supervivencia sin progresión, Quimioterapia, Inutilidad médica
File Description: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document
Access URL: http://www.jto.org/article/S1556086421020670/pdf
https://pubmed.ncbi.nlm.nih.gov/33823285
http://hdl.handle.net/10668/17534
https://pubmed.ncbi.nlm.nih.gov/33823285/
http://pubmed.ncbi.nlm.nih.gov/33823285/
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184885
https://www.ncbi.nlm.nih.gov/pubmed/33823285
https://kyushu-u.pure.elsevier.com/ja/publications/rovalpituzumab-tesirine-as-a-maintenance-therapy-after-first-line
http://www.ncbi.nlm.nih.gov/pubmed/33823285
http://hdl.handle.net/10852/91515
https://doi.org/10.1016/j.jtho.2021.03.012
https://hdl.handle.net/10668/17534 -
16
Authors: et al.
Contributors: et al.
Source: Journal of Thoracic Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Institut dInvestigació Biomèdica Sant Pau (IIB Sant Pau)
Blackhall, F, Jao, K, Greillier, L, Cho, B C, Penkov, K, Reguart, N, Majem, M, Nackaerts, K, Syrigos, K, Hansen, K, Schuette, W, Cetnar, J, Cappuzzo, F, Okamoto, I, Erman, M, Langer, S W, Kato, T, Groen, H, Sun, Z, Luo, Y, Tanwani, P, Caffrey, L, Komarnitsky, P & Reinmuth, N 2021, ' Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC : Results From the Phase 3 TAHOE Study ', Journal of Thoracic Oncology, vol. 16, no. 9, pp. 1547-1558 . https://doi.org/10.1016/j.jtho.2021.02.009
Blackhall, F 2021, 'Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study', Journal of Thoracic Oncology, vol. 16, no. 9, pp. 1547-1558. https://doi.org/10.1016/j.jtho.2021.02.009Subject Terms: Adult, Immunoconjugates, Lung Neoplasms, CELL LUNG-CANCER, Respiratory System, Delta-like protein 3, Antibodies, Monoclonal, Humanized, Rovalpituzumab tesirine, Antibodies, delta-like protein 3, 03 medical and health sciences, topotecan, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Small Cell Lung Carcinoma* / drug therapy, 3211 Oncology and carcinogenesis, Monoclonal, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, DRUG, Humanized, 1102 Cardiorespiratory Medicine and Haematology, Benzodiazepinones, Science & Technology, Small cell lung cancer, Immunoconjugates* / therapeutic use, 3202 Clinical sciences, Intracellular Signaling Peptides and Proteins, Membrane Proteins, 1103 Clinical Sciences, Middle Aged, Small Cell Lung Carcinoma, Lung Neoplasms* / drug therapy, 3. Good health, Oncology, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, rovalpituzumab tesirine, small cell lung cancer, Topotecan, Life Sciences & Biomedicine, Topotecan / therapeutic use
File Description: application/pdf
Access URL: http://www.jto.org/article/S1556086421017093/pdf
https://pubmed.ncbi.nlm.nih.gov/33607312
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4357
https://ddd.uab.cat/record/270308
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4357
https://hdl.handle.net/11370/5b367c9d-433d-46d9-85fd-1434f16876de
https://research.rug.nl/en/publications/5b367c9d-433d-46d9-85fd-1434f16876de
https://doi.org/10.1016/j.jtho.2021.02.009
https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2F49465870-3087-4310-8d76-956e77f43a8a
https://kyushu-u.pure.elsevier.com/en/publications/efficacy-and-safety-of-rovalpituzumab-tesirine-compared-with-topo
https://pubmed.ncbi.nlm.nih.gov/33607312/
https://yonsei.pure.elsevier.com/en/publications/efficacy-and-safety-of-rovalpituzumab-tesirine-compared-with-topo
https://ir.ymlib.yonsei.ac.kr/handle/22282913/185456
https://www.sciencedirect.com/science/article/abs/pii/S1556086421017093
https://ddd.uab.cat/record/270308
https://findresearcher.sdu.dk:8443/ws/files/191304579/1_s2.0_S1556086421017093_main.pdf
https://inria.hal.science/hal-03526426v1
https://doi.org/10.1016/j.jtho.2021.02.009 -
17
Authors: et al.
Source: Adv Ther
Martinez-Calle, N, Kirkwood, A A, Lamb, M, Smith, A, Khwaja, J, Manos, K, Shrubsole, C, Gray, N, Lewis, K, Tivey, A, Bishton, M J, Hawkes, E, Ahearne, M J, Osborne, W, Collins, G P, Illidge, T, Linton, K M, Cwynarski, K, Burton, C & Fox, C P 2021, 'Systemic ALCL Treated in Routine Clinical Practice : Outcomes Following First-Line Chemotherapy from a Multicentre Cohort', Advances in Therapy, vol. 38, no. 7, pp. 3789-3802. https://doi.org/10.1007/s12325-021-01764-0Subject Terms: Adult, Immunoconjugates, Lymphoma, Adolescent, Autologous stem cell transplantation, CHOEP, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Adcetris, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Anaplastic, Humans, Immunoconjugates/therapeutic use, Original Research, Aged, Retrospective Studies, Aged, 80 and over, Brentuximab Vedotin, Manchester Cancer Research Centre, Australia, Middle Aged, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, Large-Cell, 3. Good health, Brentuximab vedotin, Lymphoma, Large-Cell, Anaplastic, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, CHOP
File Description: application/pdf
Access URL: https://link.springer.com/content/pdf/10.1007/s12325-021-01764-0.pdf
https://pubmed.ncbi.nlm.nih.gov/34037958
https://eprints.whiterose.ac.uk/174675/1/Martinez_Calle2021_Article_SystemicALCLTreatedInRoutineCl.pdf
https://research.manchester.ac.uk/en/publications/c2a63144-ffac-4d6f-adfd-da0a30a507a1
https://doi.org/10.1007/s12325-021-01764-0
https://ahro.austin.org.au/austinjspui/handle/1/26628
https://www.research.manchester.ac.uk/portal/files/199598263/Martinez_Calle2021_Article_SystemicALCLTreatedInRoutineCl.pdf
https://eprints.ncl.ac.uk/275297
https://www.research.manchester.ac.uk/portal/en/publications/systemic-alcl-treated-in-routine-clinical-practice(c2a63144-ffac-4d6f-adfd-da0a30a507a1).html
http://www.ncbi.nlm.nih.gov/pubmed/34037958
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280044
https://discovery-pp.ucl.ac.uk/id/eprint/10129222/ -
18
Authors: et al.
Source: Arch Gynecol Obstet
Subject Terms: 0301 basic medicine, Immunoconjugates, Antineoplastic Agents, Mice, SCID, Antibodies, Monoclonal, Humanized, GPI-Linked Proteins, Mice, 03 medical and health sciences, 0302 clinical medicine, Cell Line, Tumor, Neoplasms, Animals, Humans, Maytansine, Cancer, 2. Zero hunger, Anti-mesothelin drug conjugates, Anetumab ravtansine, Female [MeSH], Cell Line, Tumor [MeSH], Humans [MeSH], Maytansine/therapeutic use [MeSH], Mesothelin, Animals [MeSH], Maytansine/analogs, Mice, SCID [MeSH], Immunoconjugates/therapeutic use [MeSH], Mice [MeSH], Neoplasms/drug therapy [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], GPI-Linked Proteins/therapeutic use [MeSH], Antineoplastic Agents/therapeutic use [MeSH], HeLa Cells [MeSH], Gynecologic Oncology, 3. Good health, Female, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, HeLa Cells
Access URL: https://link.springer.com/content/pdf/10.1007/s00404-020-05734-9.pdf
https://pubmed.ncbi.nlm.nih.gov/32815024
https://link.springer.com/content/pdf/10.1007/s00404-020-05734-9.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524828/
https://pubmed.ncbi.nlm.nih.gov/32815024/
https://link.springer.com/article/10.1007/s00404-020-05734-9
https://repository.publisso.de/resource/frl:6466690
https://refubium.fu-berlin.de/handle/fub188/35633
https://doi.org/10.1007/s00404-020-05734-9
https://doi.org/10.17169/refubium-35347 -
19
Authors: et al.
Contributors: et al.
Source: New England Journal of Medicine. 382:2419-2430
Subject Terms: Lung Diseases, Adult, Male, 0301 basic medicine, Immunoconjugates, Camptothecin / analogs & derivatives, Esophageal Neoplasms, Paclitaxel, Receptor, ErbB-2, Humanized / adverse effects, Camptothecin / therapeutic use, Antineoplastic Agents, Stomach Neoplasms / drug therapy, Antineoplastic Agents / therapeutic use, Adenocarcinoma, Antibodies, Monoclonal, Humanized, Irinotecan, Antibodies, 03 medical and health sciences, 0302 clinical medicine, Bone Marrow, Stomach Neoplasms, Monoclonal, 80 and over, Humans, Irinotecan / therapeutic use, Humanized / therapeutic use, Aged, Aged, 80 and over, Esophageal Neoplasms / drug therapy, Interstitial / chemically induced, Bone Marrow / drug effects, Antineoplastic Agents / adverse effects, Immunoconjugates / adverse effects, Middle Aged, Survival Analysis, Immunoconjugates / therapeutic use, 3. Good health, Adenocarcinoma / drug therapy, Camptothecin / adverse effects, ErbB-2 / analysis, Camptothecin, Female, Paclitaxel / therapeutic use, Lung Diseases, Interstitial, Receptor
Access URL: https://pubmed.ncbi.nlm.nih.gov/32469182
https://s-space.snu.ac.kr/handle/10371/173254
https://www.ncbi.nlm.nih.gov/pubmed/32469182
https://pubmed.ncbi.nlm.nih.gov/32469182/
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2004413
https://www.nejm.org/doi/full/10.1056/NEJMoa2004413
https://www.scilit.net/article/0f065665446dafb82b21c79c6d3f6e1b -
20
Authors: et al.
Contributors: et al.
Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instnameSubject Terms: Immunoconjugates, Cell Adhesion Molecules / antagonists & inhibitors, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, Receptor, ErbB-2, Camptothecin / therapeutic use, Drug Resistance, Mama - Càncer - Quimioteràpia, Breast Neoplasms / metabolism, sacituzumab govitecan, Antineoplastic Agents, Immunological, 0302 clinical medicine, Humanized / administration & dosage, Monoclonal, Immunological / administration & dosage, Molecular Targeted Therapy, HR-positive, Neoplasm Metastasis, ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica, Tumor, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Immunological / adverse effects, Breast Neoplasms / etiology, 3. Good health, Treatment Outcome, Camptothecin / adverse effects, Retreatment, Female, metastatic breast cancer, ErbB-2 / antagonists & inhibitors, Receptor, Breast Neoplasms / drug therapy, MBC, Camptothecin / analogs & derivatives, Humanized / adverse effects, Trop-2, Immunoconjugates / administration & dosage, Antineoplastic Agents, Breast Neoplasms, Antibodies, Monoclonal, Humanized, SN-38, Antibodies, 03 medical and health sciences, Metàstasi, Antigens, Neoplasm, Biomarkers, Tumor, Humans, Immunological / therapeutic use, Antigens, Humanized / therapeutic use, Neoplasm Staging, antibody–drug conjugate, Breast Neoplasms / pathology, Immunoconjugates / adverse effects, Immunoconjugates / therapeutic use, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis, Drug Resistance, Neoplasm, Neoplasm, Camptothecin, Camptothecin / administration & dosage, HER2-negative, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama, Cell Adhesion Molecules, Biomarkers, DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
File Description: application/pdf
Access URL: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0163
https://pubmed.ncbi.nlm.nih.gov/32223649
https://hdl.handle.net/11351/6446
https://www.ncbi.nlm.nih.gov/pubmed/32223649
https://pubmed.ncbi.nlm.nih.gov/32223649/
https://utsouthwestern.pure.elsevier.com/en/publications/tropics-02-a-phase-iii-study-investigating-sacituzumab-govitecan-
Full Text Finder 
Nájsť tento článok vo Web of Science 
Full Text